Diatech Diabetes
Diatech Diabetes was a pre-commercial medical device company that developed SmartFusion®, a software platform for real-time monitoring of insulin pump infusion accuracy and failure detection in people with Type 1 diabetes. Acquired by DEKA Research & Development in October 2025.
- Company typePrivate
- Founded2018
- HeadquartersMemphis, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Diatech Diabetes does
Diatech Diabetes, Inc. was a privately-held medical device company founded in 2018 and incorporated in Delaware, with operational roots in Memphis. The company developed SmartFusion®, a proprietary software platform consisting of a mobile app and an algorithm designed to monitor insulin pump infusion accuracy and detect infusion-set failures in real time. The technology is intended to integrate with insulin pumps and automated insulin delivery (AID) systems, generating alerts when failures occur and providing data to manage continuous 24/7 wear of insulin delivery devices, thereby improving safety for people living with Type 1 diabetes. At the time of acquisition, SmartFusion® was in development and not commercially available; no customers, revenue, or pricing had been established.
The company was led by co-founders John Wilcox (CEO) and Luis E. Blanco (CTO), both with personal connections to Type 1 diabetes, supported by a broader leadership team including CSO John Clark Gray and COO Nicholas Robert Cooper. Development was funded through a combination of equity raises (including Right Side Capital Management and a 2024 SEC Form D offering of up to $150,000), grant awards from Breakthrough T1D (formerly JDRF), the Consortium for Technology & Innovation in Pediatrics (CTIP), and NIH-NIDDK, and accelerator participation in ZeroTo510. The company received the 2023 Breakthrough T1D Industry Discovery & Development Partnership (IDDP) Award in recognition of its R&D progress. In October 2025, DEKA Research & Development — developer of the twiist® Automated Insulin Delivery system — acquired Diatech's core assets and intellectual property and hired select leadership, ending Diatech's operation as an independent entity and absorbing SmartFusion® into DEKA's diabetes technology portfolio.
Diatech Diabetes firmographics
Firmographics- Name
- Diatech Diabetes
- Legal name
- Diatech Diabetes, Inc.
- Website
- https://diatechdiabetes.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Diatech Diabetes was a pre-commercial medical device company that developed SmartFusion®, a software platform for real-time monitoring of insulin pump infusion accuracy and failure detection in people with Type 1 diabetes. Acquired by DEKA Research & Development in October 2025.
- Ownership category
- akta.pro rank
Diatech Diabetes industry classification
Industry- Product category
- Digital Health Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
- akta.pro secondary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
Keywords
Where Diatech Diabetes is headquartered
LocationHeadquarters
- HQ city
- Memphis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Diatech Diabetes business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Technology Licensing/Integration: Pre-commercial company developing software technology for integration with insulin pump manufacturers. Revenue model not yet established as technology is in development.
Go-to-market motion1 record
Diatech Diabetes product offering
Product offeringCore offering
Diatech Diabetes develops SmartFusion®, a software platform comprising a mobile app and proprietary algorithm that monitors insulin pump infusion accuracy and detects medication delivery failures in real-time. When integrated with an insulin pump, the platform measures daily insulin delivery accuracy, generates alerts when infusion site failures occur, and provides data to manage the continuous 24/7 wear of the device. The technology is designed to improve insulin delivery safety for people living with diabetes, particularly as automated insulin delivery systems become more prevalent.
Product overview
Diatech Diabetes developed SmartFusion®, a software platform that monitors insulin pump infusion accuracy and detects failures in real-time to improve insulin delivery safety for people with diabetes. The platform consists of the SmartFusion® algorithm and a mobile app. The technology is currently in development and not commercially available.
Differentiator
Problem solved
Functional benefit
Brands
- SmartFusion®: A software platform that monitors for medication delivery failure in infusion pumps. When integrated with an insulin pump, the SmartFusion® mobile app and algorithm measures the accuracy of daily insulin delivery, generates alerts when a failure occurs with the pump's connected infusion site, and provides data to manage the 24/7 wear of the device on the body.
Products and services
- SmartFusion®
Companies that use Diatech Diabetes
Customer profileSegments1 record
Ideal customer profiles1 record
Diatech Diabetes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature2 records
Diatech Diabetes partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- DEKA Research & DevelopmentcoreDEKA Research & Development acquired Diatech Diabetes's core assets and intellectual property in October 2025. The deal included ownership of Diatech's proprietary SmartFusion® technology and hiring of select Diatech leadership. DEKA, developer of the twiist® Automated Insulin Delivery (AID) system, viewed the acquisition as strongly aligning with their mission to develop safe and accurate diabetes technology.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Diatech Diabetes competitors and assessment
Company assessmentDirect peers
- Tandem Diabetes Care: Developer of the t:slim X2 insulin pump with Control-IQ AID technology. Tandem is a direct peer because it operates in the same AID market where SmartFusion® aims to provide infusion-accuracy monitoring, and competes for the same Type 1 diabetes customer base.
- Insulet Corporation: Maker of the Omnipod 5 tubeless patch pump with integrated AID. Insulet is a direct peer in the wearable insulin-delivery space where SmartFusion®'s continuous wear monitoring is most relevant.
- Beta Bionics: Developer of the iLet bionic pancreas AID system. Beta Bionics is a direct peer operating in the AID category with proprietary dosing algorithms where infusion-monitoring complementary software like SmartFusion® could be integrated.
- DEKA Research & Development: Acquirer of Diatech and developer of the twiist® Automated Insulin Delivery system. DEKA is the most directly comparable peer as it owns SmartFusion® and will integrate the monitoring software into its insulin pump platform.
Regional players
- Ypsomed: Swiss-based developer of the mylife Loop AID system using the YpsoPump. Ypsomed is a regional peer operating a competing AID pump platform outside the US where SmartFusion® could potentially be licensed.
Broad incumbents
- Medtronic Diabetes: Developer of the MiniMed 780G AID system with SmartGuard technology and a leading global diabetes device franchise. Medtronic is a broad incumbent peer with vertically integrated pump, CGM, and AID algorithm capabilities that could natively compete with SmartFusion®-style monitoring.
- Dexcom: Leading continuous glucose monitor (CGM) manufacturer whose sensors are integrated into most AID systems. Dexcom is a broad incumbent peer whose G7/G8 CGM data feeds AID control algorithms, making it adjacent infrastructure for SmartFusion®'s safety-monitoring use case.
Emerging players
- CamDiab: Developer of the CamAPS FX AID algorithm used with various insulin pumps across Europe. CamDiab is an emerging peer in AID control software, with overlapping interest in infusion-set monitoring and closed-loop safety.
- Tidepool: Non-profit maker of the Tidepool Loop DIY-AID-loop-derived app and diabetes data platform. Tidepool is an emerging peer operating in diabetes data software and AID control, adjacent to SmartFusion®'s monitoring software positioning.
- Bigfoot Biomedical: Developer of the Bigfoot Unity smart insulin pen system and connected diabetes management platform. Bigfoot is an emerging peer in connected diabetes drug-delivery technology with overlapping mission of simplifying and securing insulin delivery.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Diatech Diabetes social profiles
Digital presenceDiatech Diabetes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diatech Diabetes leadership team
Management profileNumber of profiles
Profiles4 records
Diatech Diabetes funding detail
Funding detailFunding overview
Funding rounds10 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diatech Diabetes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diatech Diabetes
What does Diatech Diabetes do?
Diatech Diabetes develops SmartFusion®, a software platform comprising a mobile app and proprietary algorithm that monitors insulin pump infusion accuracy and detects medication delivery failures in real-time. When integrated with an insulin pump, the platform measures daily insulin delivery accuracy, generates alerts when infusion site failures occur, and provides data to manage the continuous 24/7 wear of the device. The technology is designed to improve insulin delivery safety for people living with diabetes, particularly as automated insulin delivery systems become more prevalent.
Is Diatech Diabetes a public or private company?
Diatech Diabetes is a private company. It is classified as corporate owned and is currently acquired.
When was Diatech Diabetes founded?
Diatech Diabetes was founded in 2018. It employs 1 to 10 people.
Where is Diatech Diabetes based?
Diatech Diabetes is headquartered in Memphis, United States, in the North America region.
How does Diatech Diabetes make money?
One revenue line is on record: technology Licensing/Integration.
Who are Diatech Diabetes's main competitors?
Direct peers on record are Tandem Diabetes Care, Insulet Corporation, Beta Bionics and DEKA Research & Development. Ypsomed is listed as a regional player. Broad incumbents are Medtronic Diabetes and Dexcom. Emerging players are CamDiab, Tidepool and Bigfoot Biomedical.
Does Diatech Diabetes have an API?
No public API is recorded for Diatech Diabetes.
What industry is Diatech Diabetes in?
Diatech Diabetes's product category is Digital Health Software. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring, with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 334510 and its SIC code is 3845.